Correction: Tumor predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.
1/5 보강
[This corrects the article DOI: 10.3389/fimmu.2025.1528594.].
APA
Shimizu T, Ohkuma R, et al. (2026). Correction: Tumor predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.. Frontiers in immunology, 17, 1827736. https://doi.org/10.3389/fimmu.2026.1827736
MLA
Shimizu T, et al.. "Correction: Tumor predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.." Frontiers in immunology, vol. 17, 2026, pp. 1827736.
PMID
41972139 ↗
Abstract 한글 요약
[This corrects the article DOI: 10.3389/fimmu.2025.1528594.].
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Subcutaneous pembrolizumab: a meaningful advance in cancer treatment delivery.
- A Case with a Pathological Course Resembling Ulcerative Colitis after Rectal Cancer Surgery with Diversion.
- Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity score-matched analysis.
- Clinical and Histopathological Findings of Six Cases of Intravascular Large B-cell Lymphoma Diagnosed from 161 Random Skin Biopsy Cases.
- Operative Time as a Universal Risk Factor for Infectious Complications after Colorectal Cancer Surgery: A Multicenter Stratified Analysis by Surgical Site.
📖 전문 본문 읽기 PMC JATS · ~0 KB · 영문
In the acknowledgements, the following information was erroneously omitted: Takuya Tsunoda, Shinichi Kobayashi, and Satoshi Wada contributed to the collection of clinical data from patients, validated the reproducibility of the data analysis, and provided direction and supervision for the project.
The original version of this article has been updated.
The original version of this article has been updated.
출처: PubMed Central (JATS). 라이선스는 원 publisher 정책을 따릅니다 — 인용 시 원문을 표기해 주세요.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.